#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA2339172	F	Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as reduction of KCl-induced vasoconstriction at 0.001 uM to 10 uM treated after KCl-challenge relative to control	Rattus norvegicus	15		tissue-based format	Scientific Literature
2.	ALA2339173	B	Selectivity index, ratio of IC50 for COX1 in mouse J774 cells to IC50 for COX1 in mouse J774 cells	Mus musculus	14		cell-based format	Scientific Literature
3.	ALA2339174	B	Inhibition of Escherichia coli lipopolysaccharide-induced COX2 activity in mouse J774 cells assessed as decrease in PGE2 levels after 24 hrs by RIA	Mus musculus	14		cell-based format	Scientific Literature
4.	ALA2339175	B	Inhibition of arachidonic acid-induced COX1 activity in mouse J774 cells assessed as decrease in PGE2 levels incubated for 15 mins prior to arachidonic acid-challenge measured after 30 mins by RIA	Mus musculus	14		cell-based format	Scientific Literature
5.	ALA3880990	B	Inhibition of COX1 in mouse J774 cells using arachidonic acid as substrate assessed as decrease in PGE2 production at 10 uM preincubated for 15 mins followed by substrate addition measured after 30 mins by radioimmunoassay relative to control	Mus musculus	52		cell-based format	Patent Bioactivity Data
6.	ALA3880991	B	Inhibition of COX2 in Escherichia coli LPS-stimulated mouse J774 cells using arachidonic acid as substrate assessed as decrease in PGE2 production preincubated for 15 mins followed by substrate addition measured after 30 mins by radioimmunoassay	Mus musculus	52		cell-based format	Patent Bioactivity Data
7.	ALA3880992	F	Vasorelaxing effect in Wistar rat thoracic aorta ring assessed as reduction of KCl-induced contractile tone at 10 uM relative to KCl	Rattus norvegicus	29		assay format	Patent Bioactivity Data
8.	ALA3880993	F	Vasorelaxing effect in Wistar rat thoracic aorta ring assessed as reduction of KCl-induced contractile tone	Rattus norvegicus	29		assay format	Patent Bioactivity Data
9.	ALA3880996	F	Vasorelaxing effect in Wistar rat thoracic aorta ring assessed as reduction of KCl-induced contractile tone at 10 uM in presence of guanylate cyclase inhibitor ODQ1	Rattus norvegicus	28		assay format	Patent Bioactivity Data
10.	ALA3881004	F	Antinociceptive activity in Wistar rat assessed as weight supported on paw at 20 mg/kg, po administered 30 mins post carrageenan challenge measured after 30 mins by analgesiometer (Rvb = 33.4 +/- 3.5 g)	Rattus norvegicus	2		organism-based format	Patent Bioactivity Data
11.	ALA3881008	F	Antinociceptive activity in Wistar rat assessed as weight supported on paw at 20 mg/kg, po administered 30 mins post carrageenan challenge measured after 60 mins by analgesiometer (Rvb = 22.9 +/- 3.7 g)	Rattus norvegicus	2		organism-based format	Patent Bioactivity Data
12.	ALA3881010	F	Antinociceptive activity in Wistar rat assessed as weight supported on paw at 20 mg/kg, po administered 30 mins post carrageenan challenge measured after 120 mins by analgesiometer (Rvb = 22.9 +/- 3.7 g)	Rattus norvegicus	1		organism-based format	Patent Bioactivity Data
13.	ALA3881013	F	Antiinflammatory activity in Wistar rat assessed as volume of carrageenan-induced paw oedema at 20 mg/kg, po administered 3.5 hrs post carrageenan challenge by plethysmometer (Rvb = 2.59 +/- 0.02 ml)	Rattus norvegicus	2		organism-based format	Patent Bioactivity Data
14.	ALA3887378	B	In Vitro Inhibition Assay: The murine monocyte/macrophage cell line J774 is grown in Dulbecco's modified Eagle's medium (DMEM), enriched with glutamine (2 mM), HEPES (25 mM), penicillin (100 ug/mL), streptomycin (100 ug/mL), 10% of fetal bovine serum (FBS) and 1.2% of sodium pyruvate. The cells are distributed in 24-well plates at a density of 2.5x105 cells/mL or in culture dishes with a diameter of 10 cm (1x107 cells/10 mL/dish) and kept for 2 hours at 37° C. in a CO2 (5%)/O2 (95%) atmosphere. Just before the experiments, the culture medium is replaced with fresh medium without FBS to avoid interference during the radio-immunological phase and the cells are stimulated as described below.Evaluation of COX-1 Activity.The cells are pretreated with the test compounds for 15 minutes and then incubated for 30 minutes with arachidonic acid (15x10-6 m). At the end of incubation the supernatants are collected for evaluating, by means of radio-immunological assays, the amount of PGE2 produced.	Homo sapiens	47		assay format	BindingDB Database